|
|
 |
|
Viewing report
|
|
|
|
Zimbabwe Pharmaceuticals and Healthcare Report Q2 2008
Business Monitor International, May 2008, Pages: 63
The Zimbabwe Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Zimbabwes pharmaceuticals and healthcare industry.
Zimbabwe’s pharmaceutical sector continues to struggle under the weight of international sanctions and hyperinflation. We estimate the market to have been worth US$4.5mn in 2007 - down 9% on its 2006 value. Despite uncertainties surrounding the economic climate making long term drug market forecasts problematic, we expect the market to shrink further to US$3.7mn by 2012, taking into account thenegative real GDP growth widely expected for the economy as a whole.
A shortage of foreign currency placed severe limits on the ability of pharmacies to import drugs during the second half of 2007. According to reports in the local media, around half of drugs were out of stock in pharmacies surveyed, while those that were available had risen to prices that were multiples of local workers’ salaries.
Meanwhile, Zimbabwe’s manufacturing industry is suffering from similar constraints - with a lack of foreign currency reducing the volume of raw materials that can be imported. Problems at home have made exports a vital source of income and foreign currency. In this regard, CAPS Holdings continues to lead the way with exports to South Africa, Mozambique and Botswana. Meanwhile, Varichem Labs found another source of foreign currency - the UN Development Programme (UNDP) - which supported a US$2.1mn upgrade of its antiretroviral (ARV) manufacturing plant completed in January 2008 that is expected to ensure World Health Organisation (WHO) compliance.
In BMI’s updated business environment ratings for the Middle East and Africa, Zimbabwe scored 15 out of a possible 100 putting it in last place out of 14 markets surveyed. Its poor showing takes into account factors including a small, contracting market, unfavourable regulatory environment and challenging economic and political situation.
Fees in the healthcare sector have struggled to keep pace with inflation. Insurance in particular has suffered because premiums and benefits levels set in advance have been eroded by rises in health fees. Meanwhile, the economic crisis seems to have put pay to any chance of a national health insurance scheme, meaning that out of pocket spending is likely to continue to increase as a proportion of health expenditure.
Also available
Zimbabwe Pharmaceuticals and Healthcare Report Q1 2008
Zimbabwe Pharmaceuticals and Healthcare Report Q3 2008
Customers who bought this item also bought
Indian Healthcare Sector: An Analysis
US Healthcare Sector: An Analysis
Overview of the U.S. Healthcare Market and Implications for the Healthcare IT Industry
Radiology and Diagnostic Image Information Systems Market Opportunities, Strategies, and Forecasts, 2007 to 2013
Nigeria Pharmaceuticals and Healthcare Report Q2 2008
The Medical Device Market: USA
Nigeria Pharmaceuticals and Healthcare Report Q1 2008
Private Healthcare Market Report 2007
|
|
|
|
